● pepmg Research Desk · Peer-reviewed evidence review
What the research says about CJC-1295
A neutral summary of the peer-reviewed literature on CJC-1295, a long-acting growth-hormone-releasing hormone analogue studied in small early human pharmacology trials and animal models. No clinical outcome trials exist. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analogue studied in small early-phase human pharmacology trials and in animal models [1][2][4].
- In healthy adults it raised growth-hormone and IGF-1 levels for days after a single injection, reflecting its extended half-life [1][2].
- The human studies measured hormone levels and safety over weeks, not any clinical outcome such as muscle, fat, or performance change [1][2][3].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What CJC-1295 is
CJC-1295 is described in the literature as a synthetic analogue of growth-hormone-releasing hormone engineered to bind endogenous albumin after injection, which extends its half-life and prolongs stimulation of the pituitary to release the body's own growth hormone [2]. It is sold by third-party research-chemical vendors and is not an approved medicine; it is offered for laboratory and research use only.
The published human research on CJC-1295 consists of small, early pharmacology studies rather than clinical outcome trials [1][2][3].
What the human research has measured
Limited evidenceIn two randomized, placebo-controlled, ascending-dose trials in healthy adults, a single subcutaneous injection of CJC-1295 produced dose-dependent increases in mean growth-hormone concentrations (by about 2- to 10-fold) and IGF-I concentrations (by about 1.5- to 3-fold), with an estimated half-life of about 5.8 to 8.1 days; after multiple doses, mean IGF-I levels remained above baseline for up to 28 days [1]. No serious adverse reactions were reported in that study [1].
A separate clinical study examined growth-hormone pulsatility, reporting that CJC-1295 markedly increased trough (basal) growth-hormone levels (about 7.5-fold; p<0.0001) and raised mean growth-hormone and IGF-1 levels (by about 46% and 45%, respectively) while preserving the natural pulsatile pattern of secretion [2]. A proteomic study in healthy men identified candidate serum biomarkers of the growth-hormone and IGF-1 response to CJC-1295 [3]. In an animal model, a GHRH-knockout mouse, once-daily CJC-1295 maintained normal growth [4].
What the trials report on safety and adverse events
Limited evidenceThe human CJC-1295 studies were short and small, and their reported safety experience reflects that. The main dose-ranging trial reported no serious adverse reactions and that the compound was safe and relatively well tolerated over the weeks studied, particularly at the lower doses examined [1]. These are observations from small early-phase pharmacology studies, not evidence that long-term or physique-related use is safe.
A separate qualitative study examined online, unsupervised use of CJC-1295 for muscle enhancement, fat loss, and skin and sleep effects, and reported user-described concerns about dosing uncertainty and long-term consequences, calling for public-health awareness of self-medicating use [5]. There are no controlled human trials establishing the safety or efficacy of CJC-1295 for the body-composition or anti-aging uses for which it is marketed.
This is not medical advice. The human safety of CJC-1295 for its marketed uses is not established; consult a qualified professional and read the studies directly.
How strong is the evidence
Because the human evidence consists of small, early-phase pharmacology trials that measured hormone levels rather than clinical outcomes, supported by animal work, the evidence base is characterized as limited [1][2][4]. "Limited" describes the state of the research, not a judgment of whether CJC-1295 works or is safe.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 5
- Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
- Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
- Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse.
- Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.